Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rubinstein

Showing results (531-540 of 558) with videos related to

Pageof 56
Sort By:
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization StudySamia Shabnaz, Eric Farber-Eger, Marwa Tantawy, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 11, 2022
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservationBeryl Manning-Geist, Sushmita Gordhandas, Anjelica Hodgson, et al.
Gynecologic Oncology|November 3, 2020
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancersMaria M Rubinstein, Rachel N Grisham, Karen Cadoo, et al.
Trials|April 16, 2015
WARRIOR-trial - is routine radiography following the 2-week initial follow-up in trauma patients with wrist and ankle fractures necessary: study protocol for a randomized controlled trialNikki L Weil, M Frank Termaat, Sidney M Rubinstein, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Journal of Manipulative and Physiological Therapeutics|October 17, 2012
Chiropractic care and public health: answering difficult questions about safety, care through the lifespan, and community actionClaire Johnson, Sidney M Rubinstein, Pierre Côté, et al.
Gynecologic Oncology|December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyMaria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Pageof 56

Showing results (531-540 of 558) with videos related to

Sort By:
Pageof 56
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization StudySamia Shabnaz, Eric Farber-Eger, Marwa Tantawy, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 11, 2022
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservationBeryl Manning-Geist, Sushmita Gordhandas, Anjelica Hodgson, et al.
Gynecologic Oncology|November 3, 2020
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancersMaria M Rubinstein, Rachel N Grisham, Karen Cadoo, et al.
Trials|April 16, 2015
WARRIOR-trial - is routine radiography following the 2-week initial follow-up in trauma patients with wrist and ankle fractures necessary: study protocol for a randomized controlled trialNikki L Weil, M Frank Termaat, Sidney M Rubinstein, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Journal of Manipulative and Physiological Therapeutics|October 17, 2012
Chiropractic care and public health: answering difficult questions about safety, care through the lifespan, and community actionClaire Johnson, Sidney M Rubinstein, Pierre Côté, et al.
Gynecologic Oncology|December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyMaria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Pageof 56